GlobeNewswire: Pluri Inc. Contains the last 10 of 399 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T09:22:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/19/2848321/0/en/Engage-with-Pluri-s-Talent-Exciting-Conference-Appearances-Ahead.html?f=22&fvtc=4&fvtv=10495Engage with Pluri's Talent: Exciting Conference Appearances Ahead2024-03-19T08:00:00Z<![CDATA[HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced its participation in the following upcoming conferences.]]>https://www.globenewswire.com/news-release/2024/03/14/2846153/0/en/Pluri-Selected-as-CDMO-by-Remedy-Cell-for-Cell-Derived-Cell-Free-Drug-Manufacturing.html?f=22&fvtc=4&fvtv=10495Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing2024-03-14T11:00:00Z<![CDATA[PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) PluriCDMO™ will support Remedy Cell in the manufacture of RC-0315 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF)]]>https://www.globenewswire.com/news-release/2024/03/11/2843630/0/en/Pluri-Receives-First-Ever-Patent-Approval-for-3D-Bioreactor-Technology-in-Plant-Cell-Cultivation.html?f=22&fvtc=4&fvtv=10495Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation2024-03-11T11:00:00Z<![CDATA[Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product Patent helps position Pluri as a leader in cell expansion for the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product]]>https://www.globenewswire.com/news-release/2024/03/06/2841236/0/en/Pluri-Inc-Announces-Appointment-of-Jim-Roosevelt-Jr-to-its-Advisory-Board.html?f=22&fvtc=4&fvtv=10495Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board2024-03-06T12:00:00Z<![CDATA[HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced the appointment of attorney James Roosevelt, Jr. to the Company’s Advisory Board.]]>https://www.globenewswire.com/news-release/2024/02/28/2836820/0/en/Pluri-s-Innovation-Across-Various-Industries-CEO-Updates-on-Recent-Achievements-2024-Goals.html?f=22&fvtc=4&fvtv=10495Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals2024-02-28T12:00:00Z<![CDATA[HAIFA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (NASDAQ:PLUR) (TASE:PLUR) (“Pluri” or the “Company”) today issued the following update from CEO and President, Yaky Yanay:]]>https://www.globenewswire.com/news-release/2024/01/23/2813717/0/en/Step-into-the-Future-Pluri-Launches-Sustainable-Cell-Based-Coffee-as-Countermeasure-for-Global-Coffee-Crisis.html?f=22&fvtc=4&fvtv=10495Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis2024-01-23T07:00:00Z<![CDATA[HAIFA, Israel, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global well-being and sustainability, announced today that it has launched its cell-based coffee business activity, an innovative product that will potentially revolutionize the traditional coffee industry. Pluri’s cell-based coffee product is designed to address the growing global demand for sustainable, high-quality coffee at mass scale production.]]>Cells made into ground coffeeCells made into ground coffeePluri’s Cell-based coffeePluri’s Cell-based coffeehttps://www.globenewswire.com/news-release/2024/01/08/2805292/0/en/Pluri-Launches-Advanced-Global-Cell-Therapy-Contract-Development-and-Manufacturing-Organization.html?f=22&fvtc=4&fvtv=10495Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization2024-01-08T12:00:00Z<![CDATA[HAIFA, Israel, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote global wellbeing and sustainability, today announced it has launched a new business division offering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO): PluriCDMO™.]]>Clean Room, Pluri’s Manufacturing FacilityClean Room, Pluri’s Manufacturing Facilityhttps://www.globenewswire.com/news-release/2023/12/21/2799882/0/en/Pluri-and-Bar-Ilan-University-to-Develop-PLX-Cells-for-the-Treatment-of-Cocaine-Addiction.html?f=22&fvtc=4&fvtv=10495Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction2023-12-21T12:00:00Z<![CDATA[HAIFA, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote well-being and sustainability, announced it has signed an agreement assigning the joint patent rights to develop Pluri’s PLX cells in the treatment of cocaine addiction, to BIRAD–Research & Development Company Ltd., the commercial arm of Bar-Ilan University. Under the agreement, Bar-Ilan University via BIRAD will receive the right to further develop and commercialize PLX cells as a cocaine anti-addiction product, and Pluri is entitled to 20% revenue sharing from future sales of the product for anti-addiction.]]>PLX-PAD Cells (PAD) attenuate cocaine craving in animal model for drug addiction (level presses indicate the compulsive demand of a rat to inject cocaine intravenous)PLX-PAD Cells (PAD) attenuate cocaine craving in animal model for drug addiction (level presses indicate the compulsive demand of a rat to inject cocaine intravenous)https://www.globenewswire.com/news-release/2023/08/16/2726213/0/en/Pluri-s-PLX-R18-Increases-Blood-Cell-Counts-and-Reduces-Need-for-Transfusions-in-a-Phase-I-Study-Results-Published-in-Nature-Bone-Marrow-Transplantation.html?f=22&fvtc=4&fvtv=10495Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation2023-08-16T11:00:00Z<![CDATA[HAIFA, Israel, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote wellbeing and sustainability, today announced the publication of an article titled “Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study” in the peer reviewed journal Nature Bone Marrow Transplantation.]]>https://www.globenewswire.com/news-release/2023/07/13/2704053/0/en/Pluri-Announces-Appointment-of-Entrepreneur-Lorne-Abony-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=10495Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors2023-07-13T06:00:00Z<![CDATA[Abony: “Pluri’s cell expansion technology has extraordinary potential across a range of industries.” Abony: “Pluri’s cell expansion technology has extraordinary potential across a range of industries.”]]>Mr. Lorne AbonyMr. Lorne Abony